Benzinga - by Lisa Levin, Benzinga Editor.
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
- Cambium Networks Corporation (NASDAQ: CMBM) shares dipped 27.8% to $5.72 in pre-market trading after the company reported preliminary revenue for the third quarter. Cambium Networks said it sees revenues of $40 million to $45 million, versus prior forecast of $62 million to $70 million. The company also suspended its guidance for the full year 2023.
- MaxCyte, Inc. (NASDAQ: MXCT) shares tumbled 21.4% to $2.57 in pre-market trading. MaxCyte said it sees third-quarter total revenue of $7.8 to 8.0 million, representing a decrease of 25% -27% versus the year-ago quarter. The company now expects total revenue of approximately $34 million to $36 million for the year.
- Accolade Inc (NASDAQ: ACCD) shares declined 9.2% to $8.85 in pre-market trading after the company reported second-quarter results. Accolade said it sees FY24 revenue of $410 million to $414 million.
- Rivian Automotive, Inc. (NASDAQ: RIVN) shares 8.7% to $21.63 in pre-market trading after announcing a debt offering. Alongside this, the company also provided a preliminary print of its third-quarter revenue, which fell in line with expectations.
- Resources Connection, Inc. (NASDAQ: RGP) shares fell 8.5% to $13.25 in pre-market after the company reported first-quarter financial results.
- Nanobiotix S.A. (NASDAQ: NBTX) shares declined 8% to $8.23 in pre-market trading. Nanobiotix announced presentation of the final efficacy analysis from Phase 1 cohort expansion evaluating NBTXR3 in locally advanced head and neck cancer showing median progression-free survival of 16.9 months and median overall survival of 23.1 months.
- Lithium Americas (Argentina) Corp (NYSE: LAAC) shares fell 5% to $5.71 in pre-market trading.
- The Clorox Company (NYSE: CLX) shares fell 4.6% to $125.76 in pre-market trading after the company reported preliminary first-quarter financial results.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Don’t forget to check out our premarket coverage here
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.